Danish firm LEO Pharma has announced positive results of DELTA 1, the first of two pivotal Phase III trials with delgocitinib cream.
Being developed by LEO under a license agreement with Japan Tobacco (TYO: 2914), the investigational topical pan-Janus kinase-inhibitor is being studied for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
"There are currently no topical treatments specifically developed and approved for the treatment of moderate to severe CHE"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze